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Abstract
Background: Imiquimod (IMQ) produces a cutaneous phenotype in mice frequently studied as an acute model of
human psoriasis. Whether this phenotype depends on strain or sex has never been systematically investigated on
a large scale. Such effects, however, could lead to conflicts among studies, while further impacting study outcomes
and efforts to translate research findings.
Methods: RNA-seq was used to evaluate the psoriasiform phenotype elicited by 6 days of Aldara (5% IMQ)
treatment in both sexes of seven mouse strains (C57BL/6 J (B6), BALB/cJ, CD1, DBA/1 J, FVB/NJ, 129X1/SvJ,
and MOLF/EiJ).
Results: In most strains, IMQ altered gene expression in a manner consistent with human psoriasis, partly due to
innate immune activation and decreased homeostatic gene expression. The response of MOLF males was aberrant,
however, with decreased expression of differentiation-associated genes (elevated in other strains). Key aspects of the
IMQ response differed between the two most commonly studied strains (BALB/c and B6). Compared with BALB/c,
the B6 phenotype showed increased expression of genes associated with DNA replication, IL-17A stimulation, and
activated CD8+ T cells, but decreased expression of genes associated with interferon signaling and CD4+ T cells.
Although IMQ-induced expression shifts mirrored psoriasis, responses in BALB/c, 129/SvJ, DBA, and MOLF mice were
more consistent with other human skin conditions (e.g., wounds or infections). IMQ responses in B6 mice were most
consistent with human psoriasis and best replicated expression patterns specific to psoriasis lesions.
Conclusions: These findings demonstrate strain-dependent aspects of IMQ dermatitis in mice. We have shown that
IMQ does not uniquely model psoriasis but in fact triggers a core set of pathways active in diverse skin diseases.
Nonetheless, our findings suggest that B6 mice provide a better background than other strains for modeling psoriasis
disease mechanisms.
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Background
The study of psoriasis has been hindered by the lack of a
mouse phenotype that fully recapitulates the complex
features of lesions in psoriasis patients [1, 2]. In recent
years, topical application of imiquimod (IMQ) cream
(Aldara™) to murine skin has increasingly been used as
an acute psoriasiform murine model, in part due to its
convenience and ability to elicit a dermatitis resembling
some aspects of psoriasis [3, 4]. IMQ is a Toll-like recep-
tor (TLR7/8) agonist that can be applied to mouse skin
to elicit erythema, scaling, keratinocyte (KC) prolifera-
tion with acanthosis, altered KC differentiation (paraker-
atosis), and a dermal infiltrate that includes T cells [3].
The phenotype additionally involves induction of IL-17/
IL-23 axis cytokines (e.g., IL-17A, IL-17 F, IL-22 and IL-
23) and is partially dependent upon IL-23, IL-17 family
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cytokines, and the presence of T lymphocytes [3, 5, 6].
All of these features are consistent with human psoriasis
lesions and accepted models of cutaneous lesion devel-
opment [1, 2]. IMQ has thus been viewed as a conveni-
ent and easy-to-use mouse model of acute inflammatory
response, which has been applied to facilitate mechanis-
tic studies that would otherwise prove difficult or impos-
sible to perform in humans.
Psoriasis is a complex genetic disease that depends
upon interactions among environmental influences and
disease variants at multiple loci [7]. Given this genetic
basis, it is reasonable to expect that any realistic mouse
model of psoriasis would be sensitive to genetic back-
ground, with certain aspects of the psoriasiform pheno-
type varying among mouse strains. Most studies of
IMQ-induced lesions in mouse are performed using one
strain (often B6 or BALB/c) and commonly only one sex
has been investigated (frequently females) [4, 8]. It is not
unusual for either the strain or sex of experimental ani-
mals to go unreported in published research [8], and the
question of whether mechanistic findings are sensitive to
genetic background or sex is seldom addressed. Those
few studies that have analyzed multiple mouse strains,
however, suggest that IMQ responses can be strain-
specific [4, 9]. For example, BALB/c lesions develop
more rapidly than B6 lesions following IMQ application
[3, 4]. B6 mice may also have less severe systemic re-
sponses, which include dehydration leading to weight
loss and decreased activity levels [3]. Even the more
closely related C57BL/6 J and C57BL/6 N substrains
were recently shown to exhibit differential IMQ re-
sponses, with C57BL/6 J mice exhibiting increased
erythema, desquamation, epidermal proliferation, and
skin inflammation [9]. It has been suggested that differ-
ences in IMQ response among these genotypes (C57BL/
6 J, C57BL/6 N, and BALB/c) may be related to cutane-
ous IL-22 activation [3, 9], although other possibilities
have not been investigated systematically.
The practical significance of strain-specific IMQ
responses is that studies utilizing different strains may
reach conflicting conclusions regarding the cell types,
mediators, and pathways required for the psoriasiform
phenotype [10]. This has been observed for other
inflammatory skin phenotypes in mice [11] and can di-
minish the apparent repeatability of experimental find-
ings, potentially leading to misdirected research effort
and mechanistic conclusions that cannot be generalized
[12, 13]. Examples illustrating genetic background as a
possible pitfall in mechanistic studies are abundant and
can be drawn from numerous contexts and model
organisms [14–17]. Addressing these issues requires
systematic investigation of IMQ responses in multiple
mouse strains to better understand the degree to which
the psoriasiform phenotype is sex- and strain-dependent.
At the molecular level, this can lead to identification of
pathways that respond similarly to IMQ regardless of
genotype, which may in turn represent the most reliable
center points for mechanistic investigations. At the same
time, those responses that are strain-dependent may
point towards allelic variants that shape innate immune
responses, suggesting new avenues for studies of gene
function [18]. Ultimately, such investigation should help
refine the IMQ model by clarifying its strengths and
limitations relative to human psoriasis, which should
improve the chance that new findings are successfully
translated to clinical studies with patients [12].
This study used RNA-seq to investigate the psoriasi-
form phenotype that develops following topical Aldara
(5% IMQ) treatment in male and female mice of seven
laboratory mouse strains (C57BL/6 J (B6), BALB/cJ,
CD1, DBA/1 J, FVB/NJ, 129X1/SvJ, and MOLF/EiJ) [19].
The IMQ psoriasiform phenotype has previously been
evaluated using microarrays [2, 20–22], but to our
knowledge has not yet been evaluated by RNA-seq.
Previously, we used microarrays to compare cutaneous
phenotypes of five psoriasis mouse models and to score
the similarities and differences of such models relative to
human psoriatic plaques [2]. Following the same
principle, the current analysis uses RNA-seq to evaluate
the IMQ psoriasiform phenotype that manifests in males
and females from seven strains. These strains include
one representative from each major group identified
from genetic analysis of existing mouse diversity [23].
Six of seven strains are inbred, but CD1 is an outbred
strain maintained with minimal inbreeding to retain het-
erozygosity and genetic diversity [24]. Our goals were to
evaluate the degree to which transcriptome-level IMQ
responses depend on strain and sex and to distinguish
shared responses from those that are strain- or sex-
specific. We additionally identify genes, pathways, and
cell types similarly altered in mouse phenotypes and
human psoriasis, as well as discordant patterns repre-




Male (n = 5/strain) and female (n = 5/strain) mice were
purchased at 8 weeks of age and allowed 14 days to
acclimate prior to starting experiments. Most strains
were purchased from the Jackson Laboratory (C57BL/6 J
(B6), catalog number 000664; BALB/cJ, catalog number
000651; DBA/1 J, catalog number 000670; FVB/NJ, cata-
log number 001800; 129X1/SvJ, catalog number 000691;
MOLF/EiJ, catalog number 000550). CD1 (ICR) mice
were purchased from Charles River laboratories (catalog
number 022). Mice were maintained within the Case
Western Reserve University animal vivarium under
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specific-pathogen-free conditions and provided standard
rodent chow diet (4.5% fat by weight, 14% kcal, Lab Diet
P3000).
Imiquimod protocol
A topical dose of 62.5 mg IMQ cream (5% Aldara; 3 M
Pharmaceuticals) was applied daily to the shaved back
region of mice. Control (CTL) animals were treated
similarly with a non-toxic lanolin-derived occlusion
cream (VWR, catalog number 56614-414). Mice in the
CTL group did not exhibit macroscopic indications of
skin irritation or inflammation (e.g., erythema, scaling,
or induration). IMQ and CTL treatments were carried
out for 5 consecutive days and mice were sacrificed on
day 6 following injection with euthanasia solution
(ketamine, 16.5 mg/mL; xylazine, 1.65 mg/mL) followed
by cervical dislocation. Mice were weighed daily and
provided saline (i.p.) as needed to supplement fluid loss
associated with IMQ treatment, a well-known side effect
[25]. This limited weight loss in most strains, although
we note that one of five MOLF males and one of five
MOLF females died prior to day 6. Samples from these
mice were excluded from analyses, but for all other mice
back skin and spleens were collected immediately upon
sacrifice on day 6, flash frozen, and stored at −80 °C
prior to isolation of total RNA. Skin adjacent to that col-
lected for RNA was placed into formalin and processed
for histology. For all strains, tissues were collected at ap-
proximately the same time of day to limit gene expres-
sion variation associated with circadian rhythms [26].
Body weight, epidermal thickness, and spleen weight
Body weight was measured in all mice before onset of
treatments and prior to sacrifice. Spleens from each
mouse were removed and weighed immediately follow-
ing sacrifice. Formalin-fixed paraffin-embedded skin was
sectioned and stained with H&E. Epidermal thickness
measurements were completed blind to treatment, back-
ground strain, and sex as described previously [27, 28].
For each strain, CTL and IMQ groups were compared
with respect to body weight change (post-treatment
versus pre-treatment), epidermal thickness, and spleen
weight using linear models with simultaneous evaluation
of contrasts (IMQ versus CTL) based upon the exact
multivariate t-distribution (R package, multcomp; func-
tion, glht; Fig. 1b–d). Comparisons among the 14
strain–sex groups for each strain and treatment were
carried out using Tukey’s honest significance test with
an experiment-wise type I error rate of 0.05 (R package,
agricolae; R function, HSD.test). Epidermal thickness
required log10-transformation to improve normality of
the distribution, whereas body weight change and
spleen weight were analyzed without transformation
(Additional file 1).
RNA-seq expression profiling
RNA-seq expression profiling was completed on ran-
domly chosen mice (n = 2 for each sex, strain, and treat-
ment). Total RNA was extracted from flash-frozen skin
samples using the RNeasy Fibrous Tissue Mini Kit
(Qiagen, catalog number 74704) with on-column DNase
digestion (Qiagen, catalog number 79254). RNA concen-
trations were evaluated using the NanoDrop spectropho-
tometer and RNA integrity was assessed using the Agilent
Bioanalyzer. RNA was further assessed for quality using
the TapeStation (Agilent, Santa Clara, CA, USA) with the
manufacturer’s recommended protocols. All samples had
RNA integrity numbers of 8 or greater.
Samples were prepped using the Illumina TruSeq
mRNA Sample Prep v2 kit (catalog numbers RS-122-
2001 and RS-122-2002; Illumina, San Diego, CA, USA)
following the manufacturer’s recommended protocols,
with 0.1–3.0 μg of total RNA converted to mRNA by
poly(A) purification. mRNA was then fragmented and
copied into first strand cDNA using reverse transcriptase
and random primers. The 3′ ends of cDNA were then
adenylated and adapters were ligated. One adapter had a
six-nucleotide barcode unique to each sample, which
allowed multiple samples to be sequenced in each lane
of a HiSeq flow cell (Illumina). Products were purified
and enriched by PCR to create the final cDNA library.
Final libraries were checked for quality and quantity by
TapeStation (Agilent) and quantitative PCR using Kapa’s
library quantification kit for Illumina Sequencing
platforms (catalog number KK4835; Kapa Biosystems,
Wilmington, MA, USA). They were then clustered on
the cBot (Illumina) and sequenced six samples per lane
on a 50 cycle single end HiSeq 2000 (Illumina) in high
output mode (version 3 reagents).
An average of 35.5 million 50-bp reads was generated
from the 56 samples (Additional file 2). The adaptor se-
quence was removed using the cutadapt algorithm with
5% maximum error rate (-e option) and 20-bp minimum
read length (-m option) [29]. Low quality reads were
removed using the cutadapt running sum quality filter
with Phred33 quality threshold of 25 (-q option) and 20-
bp minimum read length (-m option) [29, 30]. Reads
were also quality filtered using the window-based algo-
rithm within the FASTX-Toolkit (fastq_quality_filter),
which excluded reads without phred33 score greater
than 25 for at least 50% of the read length (options -q
25 -p 50) [30, 31]. The FASTX-Toolkit artifacts filter
(fastx_artifacts_filter) was applied [31]. Read statistics
and quality prior to mapping were assessed using the
“fastx_quality_stats” utility [31] and FastQC [32].
Reads were mapped to the mouse genome (GRCm38/
mm10) using TopHat2 [33] along with UCSC Genome
Browser gene model annotations and Bowtie index files
[34]. The TopHat2 coverage based search for junctions
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was disabled (–no-coverage-search) as well as mapping
of reads to multiple locations (option -g 1) [33]. Bam
files generated by TopHat2 were sorted, indexed, and
further analyzed using samtools [35]. The number of
reads mapping to each annotated gene was tabulated
using HTSeq (function, htseq-count) and only reads
completely and unambiguously overlapping a gene locus
were included in tabulations (-m intersection-strict)
[36]. Reads with alignment quality scores less than 10
were excluded (-a 10) [36]. Cufflinks was used to calcu-
late fragments per kilobase of transcript per million
mapped reads (FPKM) and associated FPKM confidence
intervals [37]. Mapping quality assessments including
the percentage of total mapped reads and percentage of
exonic reads were generated using RSeQC [38] and
RNA-SeQC [39].
Differential expression analysis
Differential expression analysis was performed to iden-
tify genes with normalized read counts differing between
IMQ- and CTL-treated samples. For each sex–strain
combination, this comparison involved four samples
(two IMQ-treated and two CTL-treated) and considered
only genes with expression detected in at least one of
the four samples. Genes were considered to have de-
tected expression in a sample if the count per million
mapped reads (cpm) was greater than 0.25 and if the
FPKM lower 95% confidence interval was greater than 0.
Fig. 1 Cutaneous and systemic IMQ responses. a IMQ dermatitis in B6, BALB/c, and MOLF mice. b Weight loss following IMQ treatment (*P < 0.05,
IMQ versus sex-matched control). c Epidermal thickness (*P < 0.05, IMQ versus sex-matched control; measured using microscopy). d Spleen weight
(*P < 0.05, IMQ versus sex-matched control). e–g CTL-treated samples. h–j IMQ-treated samples. In e–j, groups without the same letter differ
significantly (P < 0.05, Tukey honest significant difference). In b–j, three to five mice were evaluated for each strain, sex, and treatment (error bars
represent standard error of the mean). F female, M male
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Tests for differential expression were performed using
negative binomial generalized log-linear models as im-
plemented within the R Bioconductor package edgeR
[40]. To correct for library size differences among sam-
ples, gene counts were normalized using the trimmed
mean of M-values (TMM) method (edgeR function, calc-
NormFactors) [41]. Within the negative binomial frame-
work, dispersion parameters are estimated for each gene
to quantify inflation of gene-specific variances relative to
the Poisson probability distribution model [42]. These
dispersions were estimated using the Cox-Reid Ad-
justed Profile Likelihood method (edgeR functions, esti-
mateGLMTrendedDisp and estimateGLMTagwiseDisp)
[40, 42]. Negative binomial models were then fit for
each gene (edgeR function, glmFit) and p values for dif-
ferential expression were obtained by likelihood ratio
tests (edgeR function, glmLRT) [40]. Raw p values were
adjusted for multiple hypothesis testing using the
Benjamini–Hochberg method [43]. The same differential
expression analysis methods were applied to identify genes
differing significantly in pairwise comparisons of CTL
samples from different strains. To identify genes with sex-
dependent IMQ responses, negative binomial models with
likelihood ratio tests were used (edgeR function, glmLRT),
with full models for each gene formulated to include covar-
iates corresponding to sex, treatment, and sex × treatment
interaction, and reduced models including covariates corre-
sponding to sex and treatment only.
Mouse–human homology mapping
Vertebrate homology maps were downloaded from the
Mouse Genome Database (http://www.informatics.jax.
org) [44]. Homology maps included 16757 homologene
identifiers uniquely associated with a mouse and human
gene symbol. This allowed matching of mouse and hu-
man expression data based upon gene symbols sharing a
common homologene identifier.
Additional gene expression datasets
Gene expression in human psoriasis was evaluated using
results from an RNA-seq meta-analysis comparing gene
expression in psoriasis lesions to uninvolved skin from
44 patients (Gene Expression Omnibus (GEO) series
identifiers GSE41745, GSE54456/GSE63979, GSE66511)
[45]. Additional datasets incorporated into analyses in-
clude those from prior microarray studies of IMQ
dermatitis in mice (GSE27628, GSE47607, GSE60804,
GSE63684, GSE78057) [2, 20–22], human KCs treated
with poly(I:C) (GSE21260) [46], human KCs treated with
IL-17A (GSE12109, GSE24767, GSE27533, GSE32620,
GSE36287, GSE52361, GSE53751), the Immunological
Genome Project (IGP; GSE15907) [47, 48], macroscopic-
ally normal human skin from control subjects without
skin disease (n = 90 subjects; GSE54456; Additional file
2), laser capture microdissected human suprabasal and
basal epidermis (GSE42114) [49], regenerated human epi-
dermis organotypic cultures (GSE52953) [50], Mediterra-
nean spotted fever eschars (GSE32993), burn wound
margins 0–3 days post-injury (GSE8056) [51], and Leish-
mania braziliensis-infected cutaneous lesions (GSE55664)
[52]. Comparisons to 35 human skin diseases were made
using a database of 124 expression signatures compiled
and described in a previous publication [45]. IGP data
were processed and analyzed to identify cell type-specific
genes as described previously [47]. For all other datasets,
normalized expression data were downloaded as series
matrix files, with the exception of Affymetrix datasets for
which raw CEL files were downloaded and normalized
using robust multichip average (RMA) [53]. Tests for dif-
ferential expression were performed using empirical Bayes
linear models (R package, limma) [54] with raw p values
corrected using the Benjamini–Hochberg algorithm [43].
Real time quantitative reverse transcription PCR
The 7900HT Fast Real-time PCR system with Fast 384-
well Block Module was used to carry out RT-PCR reac-
tions (Applied Biosystems, catalog number 4309849).
Pre-designed TaqMan® primer assays were purchased
from Thermo Fisher Scientific (Stat1, Mm00439531_m1;
Irf1, Mm01288580_m1; Epgn, Mm00504344_m1; Cd3g,
Mm00438095_m1; Cd4, Mm00442754_m1; Cd8a, Mm
01182107_g1; Cyp2g1, Mm01168480_m1; Fosb, Mm
00500401_m1; Aldh1l2, Mm00463499_m1; Atp13a5,
Mm00558722_m1; P2rx1, Mm00435460_m1; Il17a, Mm
00439618_m1; Il17b, Mm01258783_m1; Il17c, Mm
00521397_m1; Il17d, Mm01313472_m1; Il17e, Mm
00499822_m1; Il17f, Mm00521423_m1; Il1f5, Mm
00497802_m1; Krt1, Mm00492992_g1). 18S ribosomal
RNA (Rn18s) was used as an endogenous control gene
to normalize cycle threshold values (Applied Biosystems,
catalog number Mm04277571_s1). The 2-ΔΔCt method
was used to calculate fold changes and estimate relative
expression among samples [55]. Statistical analyses were
performed using log2-scaled estimates of relative gene
expression (i.e., Rn18s CT −Target gene CT). Group dif-
ferences in relative expression were evaluated by Tukey’s
honest significance test with an experiment-wise type I
error rate of 0.05 (R package, agricolae; R function,
HSD.test). Differential IMQ responses between strains
were evaluated using linear models with coefficients
corresponding to strain, sex, treatment, and strain-by-
treatment interaction terms (R function, lm).
Results
Mouse strains differ in their baseline characteristics but
macroscopic IMQ responses are consistent
Mouse back skin was treated with 62.5 mg Aldara™ (5%
IMQ) or a non-toxic lanolin-derived occlusion cream
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(CTL) once per day for five consecutive days. Superficial
erythema and scaling was similar among strains (Fig. 1a)
with consistent splenomegaly (Fig. 1d) and increased
epidermal thickness (acanthosis) (Fig. 1c). IMQ reduced
body weight in most strains, but this was significant only
in B6, DBA, FVB, and 129/SvJ mice (Fig. 1b). Unexpect-
edly, CTL treatment of BALB/c mice decreased body
weight significantly (Fig. 1e), and consequently there was
no difference between effects of CTL and IMQ on body
weight in this strain (Fig. 1b). Otherwise, with or with-
out IMQ treatment, strains varied continuously with
regard to epidermal thickness, weight loss, and spleen
weight (Figs. 1e–j). MOLF mice were the most dispar-
ate, with high epidermal thickness, low spleen weight,
and no significant weight loss following IMQ treat-
ment (Fig. 1e–j). Thickness of CTL-treated skin of
MOLF males, for example, was increased twofold
relative to FVB males (Fig. 1f ).
Genome-wide expression responses to IMQ differ
prominently in MOLF males
RNA-seq was used to profile transcriptomes of 56 CTL-
and IMQ-treated skin samples (7 strains × 2 sexes × 2
treatments; n = 2 samples per strain/sex/treatment com-
bination). An average of 34.9 million quality-filtered
reads was generated from the 56 samples, and of these
97.2% on average mapped to the mouse genome (UCSC
GRCm38/mm10; Additional file 2). As expected, the
proportion of mapped reads differed among strains, al-
though at least 95% of reads on average were mapped
for all strains (Additional file 2). Of mapped reads, an
average of 87.6% mapped to annotated exons, and this
percentage differed only slightly among strains and was
no less than 86% for any genotype (Additional file 2).
For each strain, expression of genes in CTL skin was
correlated with that of homologous genes in normal
human skin (rs ≥ 0.816; Additional file 3a–h), and genes
most highly expressed in human skin likewise had ro-
bust expression in mouse CTL skin (e.g., Krt1, Krt14,
Rpl37a; Additional file 3i).
Cluster analysis of protein-coding gene expression pro-
files grouped IMQ samples apart from CTL samples
(Additional file 4). Most expression variation was
explained by mouse strain (Additional file 4e), with
expression profiles of B6, BALB/c, DBA, and 129/SvJ
genotypes differing from MOLF, CD1, and FVB
(Additional file 4). Consistent with this, strain variation
was prominent among CTL samples, with differential
expression analysis suggesting that baseline expression
differed most in B6 and MOLF strains (false discovery rate
(FDR) <0.10; Additional file 3j). Despite such baseline ex-
pression differences, IMQ response vectors of MOLF and
CD1 mice were aberrant within two-dimensional principal
component space, particularly among males (Fig. 2a, b).
MOLF males were most atypical and IMQ-induced
expression shifts were negatively correlated with other
strains (Fig. 2c, d). Consistent with this, we identified self-
organizing map regions with opposite IMQ responses in
MOLF males (Fig. 2e).
Sex-specific IMQ responses differ among strains and are
strongest in MOLF and FVB mice
In relative terms, most expression variation was ex-
plained by strain and treatment (IMQ versus CTL), with
less variation explained by sex (Additional file 4e).
Consistent with this, IMQ expression responses were
positively correlated between sexes for each strain
(Additional file 5). The magnitude of such correlations,
however, varied considerably (0.152 ≤ rs ≤ 0.799), with
weaker correlations in MOLF and FVB strains (rs = 0.152
and 0.267, respectively; Additional file 5). In line with
this, we identified 350 and 422 genes with significant
sex-by-treatment interaction effects in MOLF and FVB
mice, respectively, but few or no genes with such effects
in other strains (FDR <0.10; Additional file 5I). Genes
with significant interaction effects in MOLF and FVB
mice were largely distinct with little overlap (Additional
file 5k). By applying a less stringent significance criterion
(P < 0.05), it was possible to identify some genes with the
same sex-by-treatment interaction pattern in as many as
three or four strains (e.g., Cyp2g1, Aldh1l2; Additional
file 5l–p). Of these, the most consistent trend was ob-
served for a cytochrome P450-encoding gene (Cyp2g1),
which in five of seven strains was decreased by IMQ in
males but increased by IMQ in females (P < 0.05 for
each of five strains; Additional file 5l). Consistent sex-
specific IMQ responses were thus observed for some
genes, although no gene showed a consistent sex-specific
pattern across all seven strains (Additional file 5).
IMQ activates immune and inflammatory gene expression in
all strains but decreases expression of homeostatic genes
The number of genes with detectable expression was
similar in all strains (Fig. 3a), but the number of differ-
entially expressed genes (DEGs) between CTL and IMQ
skin varied, ranging from 35 (CD1 males) to 2676 (B6
females) (Fig. 3b). This reflected IMQ effect size differ-
ences, since the distribution of fold change estimates
(IMQ/CTL) was compressed in strains with few DEGs
(e.g., CD1 mice, BALB/c males, MOLF females; Fig. 3c).
Among the 14 strain–sex combinations, the number of
DEGs identified was negatively correlated with baseline
(CTL) body weight and spleen weight (rs = −0.42 and −0.37,
respectively), although this trend was not statistically sig-
nificant (P ≥ 0.141; Additional file 6). Genes consistently el-
evated by IMQ were associated with peptide cross-linking,
inflammation, and immune/defense response (e.g., Fcrl5,
Cd300e, Fpr1; Fig. 3d, f). Genes consistently decreased by
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IMQ (e.g., Sema3d, Mrgprb3, Retnla) were associated with
homeostasis and transport (Fig. 3e, g).
Fold changes (IMQ/CTL) estimated by RNA-seq were
usually correlated with those from previous microarray
studies [2, 20–22], but the strength of such correlations
varied by strain and among array experiments (Add-
itional file 7a–d). Correspondence was weaker relative to
one microarray study utilizing ear skin, rather than back
skin, suggesting that site of application is influential
(Additional file 7b). Although RNA-seq/microarray FCs
were correlated, we nonetheless identified 719 DEGs
induced by IMQ in B6 and/or BALB/c mice (the previ-
ously studied strains), which had not reached the same
significance thresholds in microarray experiments (fold
change >2.0 with FDR <0.10; Additional file 7c). Similarly,
we identified 1407 IMQ-repressed DEGS not identified
Fig. 2 Genome-wide expression responses to IMQ. a, b Imiquimod principal component response vectors for a males and b females (arrow start,
CTL sample average; arrow end, IMQ sample average). c Spearman correlations between fold change (FC) estimates (IMQ/CTL). d Comparison
of FC estimates (IMQ/CTL) of each strain to B6 mice of the same sex (top, males; bottom, females; white font, Spearman correlation coefficient).
Colors reflect gene density (see scale). e Self-organizing maps (SOMs). Genes are plotted on the same SOM for each sex/strain and the color scale
denotes FC (IMQ/CTL). F female, M male
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Fig. 3 Differential expression with IMQ treatment. a Number of expressed protein-coding genes. b Number of differentially expressed genes
(DEGs; IMQ-increased, fold change (FC) >2.0 with FDR <0.10; IMQ-decreased, FC <0.50 with FDR <0.10). c FC distributions (IMQ/CTL). Boxes outline
the middle 50% of FC estimates (whiskers, 10th and 90th percentiles). d, e Genes most frequently increased (d) or decreased (e) by IMQ treatment.
f, g Gene Ontology biological process terms significantly overrepresented among genes most frequently increased (f) and decreased (g) by IMQ.
Values in parentheses (left margin) indicate the total number of IMQ-increased (f) or IMQ-decreased (g) genes associated with each term. The right
margin lists example IMQ-increased/decreased genes associated with each term. F female, M male
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previously by microarray (B6 and/or BALB/c; fold change
<0.50 with FDR <0.10; Additional file 7c). Key cytokine-
encoding genes were among those identified by RNA-seq
but not in prior microarray experiments (e.g., Il17c, Il21r,
Il18, Il20; B6 and/or BALB/c; Additional file 7e, f ).
Correspondence with human psoriasis varies among
mouse strains and is non-significant for genes decreased
by IMQ in MOLF males
Genes altered by IMQ in B6 mice were previously
shown to exhibit similar expression shifts in human
psoriasis lesions (r = 0.21) [2]. For 12 of 14 sex–strain
combinations, fold changes (IMQ/CTL) were even more
strongly correlated with psoriasis (lesional/uninvolved
skin) than estimated previously [2], with an estimated
correlation of 0.45 in B6 males (Additional file 8a). The
correlation magnitude, however, varied considerably and
ranged from 0.05 (MOLF males) to 0.45 (B6 males)
(Additional file 8a). There was no significant tendency
for psoriasis-decreased DEGs to be similarly repressed
by IMQ in MOLF males, although this was the case
for each of the 13 other sex–strain combinations
(Additional file 8c). Of the 50 genes most strongly ele-
vated in psoriasis lesions, none were significantly in-
duced by IMQ in all strains, although we could
identify some induced in most except MOLF males
(e.g., Serpin3a, Serpin3d, Klk9, Klk13; Additional file
8d). Similarly, none of the 50 genes most strongly re-
pressed in psoriasis lesions were significantly re-
pressed by IMQ in all strains (Additional file 8e).
Notably, some genes strongly decreased in psoriasis
lesions were elevated by IMQ in most strains (Syt8,
Cdhr1, Cntn2; Additional file 8e). The IMQ/psoriasis
correspondence, therefore, was better than estimated
previously using microarray [2], but nonetheless im-
perfect and dependent upon strain and sex.
Anti-viral and mitotic pathways activated in psoriasis
lesions have strain-dependent responses to IMQ in mice
We identified Gene Ontology (GO) biological process
(BP) terms significantly overrepresented among genes
with elevated expression in psoriasis lesions and evalu-
ated whether corresponding mouse genes were similarly
altered by IMQ (Fig. 4a). In most strains, psoriasis-
increased genes associated with DNA replication and
mitosis were induced by IMQ (Fig. 4a). BALB/c males,
however, were an exception and in many cases such
genes were not altered or decreased (e.g., Ccnb1, Ncapg;
Fig. 4c). Consistent with this, there was a trend towards
increased expression of epithelial mitogen (Epgn) with
IMQ treatment in B6 but not BALB/c mice (Fig. 4f; P =
4.96 × 10−5, strain-by-treatment interaction).
IMQ induced expression of psoriasis-increased genes
associated with immune and inflammatory response
(Fig. 4a). However, psoriasis-increased genes associated
with viral genome replication were induced by IMQ in
MOLF, 129/SvJ, and BALB/c strains but not B6, DBA,
and FVB (Fig. 4a). We thus examined genes elevated in
psoriasis lesions and induced in human KCs following
treatment with poly(I:C) (e.g., Ehf, Nfkbiz, Zc3h12a;
Fig. 4b) [46]. These genes were variably altered by IMQ
in mouse strains, with opposite IMQ responses depend-
ing on strain (Fig. 4b), and several encoded transcription
factors mediating response to viral RNA and interferon
(e.g., Stat1 and Irf1; Fig. 4d, e).
Genes with decreased expression in psoriasis lesions
were frequently associated with homeostasis, transport,
metabolism, and development (Additional file 9a), par-
tially consistent with the core set of genes downregu-
lated by IMQ across mouse strains (Fig. 3g). Many
homeostatic and transport genes most strongly de-
creased in psoriasis were similarly repressed by IMQ, al-
though a number of these were increased in MOLF
males (Additional file 9b, c).
IMQ induces stronger activation of the IL-17A pathway in
B6 compared to BALB/c mice
Psoriasis is a cytokine-driven disease and manipulation
of cytokine-encoding genes impacts the mouse IMQ
phenotype [4]. We thus evaluated expression of genes
encoding cytokines and chemokines, as well as genes
associated with cluster of differentiation proteins on the
surface of immune cells (Fig. 5). Cytokines and chemo-
kines with increased expression in human psoriasis were
often similarly elevated by IMQ, but there was no case
in which such genes were similarly and significantly al-
tered in both sexes and all strains (Fig. 5a, c). Expression
of Il1f5, Il1f6, Il1f8, and Il1f9 was elevated in human
psoriasis and most strains except MOLF males (Fig. 5a).
Expression of IL-17 family cytokines, including Il17a,
Il17b, Il17c, and Il17f, was differentially altered by IMQ
among strains, with IMQ-increased expression in B6
mice and IMQ-decreased (or unaltered) expression in
BALB/c mice (Fig. 5a). These trends were confirmed by
RT-PCR (n = 5 per strain/sex/treatment group; P ≤ 0.037,
strain-by-treatment interaction; Additional file 10). Consist-
ent with this, genes induced by IL-17A in cultured human
KCs were more strongly elevated by IMQ in B6 relative to
BALB/c mice (Fig. 5d). Of 33 genes induced by IL-17A in
human KCs, 21 were induced by IMQ in B6 mice, but only
six were induced by IMQ in BALB/c mice (Fig. 5e).
Innate immune responses to IMQ are consistent among
strains but T lymphocyte expression differs by strain
Activation of cytokine pathways by IMQ may differ in
mouse strains due to disparities in the abundance of infil-
trating immune cells. We thus used microarray data from
the Immunological Genome Project (IGP) to identify
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Fig. 4 Gene Ontology (GO) biological process (BP) terms enriched among psoriasis-increased DEGs and correspondence with IMQ responses.
a Psoriasis-enriched GO BP terms. The heatmap shows average IMQ responses of ten representative mouse homologs for each GO BP term.
Chosen genes are homologous to the ten human genes associated with the listed term for which expression was most strongly elevated in
psoriasis lesions (i.e., lowest p value). b Psoriasis-increased DEGs induced by poly(I:C) in cultured human KCs. c Genes associated with “organelle fission”
(GO:0048285) (*FDR <0.10, IMQ versus CTL). d–f RT-PCR analysis of Stat1 (d), Irf1 (e), and Epgn (f) expression (n ≥ 4 per strain/sex/treatment group;
n = 38–40 mice total). Groups without the same letter differ significantly (P < 0.05, Tukey honest significant difference. Error bars represent standard
error of the mean; p values strain-by-treatment interaction effect). Rn18s was used as an endogenous control to estimate relative gene expression.
F female, FC fold change, M male, PN uninvolved skin from psoriasis patients, PP lesional skin from psoriasis patients, qPCR quantitative PCR
Swindell et al. Genome Medicine  (2017) 9:24 Page 10 of 21
Fig. 5 Cytokine, chemokine, and cluster of differentiation gene expression. a–c Genes encoding cytokines (a), cluster of differentiation proteins
(b), and chemokines (c). d Genes induced by IL-17 family cytokines (human KCs). Heatmap colors depict average IMQ response of 50 genes
most strongly induced in each experiment (left margin; *HaCaT; **reconstituted epidermis; cytokine concentration and exposure time shown in
parentheses). e Genes most frequently induced in six experiments from d in which KCs were treated with IL-17A alone. F female, FC fold change,
M male, PN uninvolved skin from psoriasis patients, PP lesional skin from psoriasis patients
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signature genes specifically expressed by sorted immune
cell populations [47, 48] and evaluated whether expression
of such genes is systematically altered in IMQ-treated skin
and human psoriasis (Fig. 6).
Both IMQ dermatitis and psoriasis showed increased
expression of immune cell-expressed genes and de-
creased expression of genes expressed by resident cell
types (e.g., fibroblasts and epithelial and endothelial
cells; Fig. 6a). Consistent with human psoriasis, IMQ
increased expression of genes expressed by innate im-
mune cells (e.g., macrophages, monocytes, and granulo-
cytes; Fig. 6a). On the other hand, Langerhans and
dendritic cell (DC)-expressed genes were weakly altered
in human psoriasis but variably affected by IMQ in dif-
ferent strains (Fig. 6a).
Genes encoding CD3 antigen were repressed by IMQ
in B6 mice but not BALB/c mice, suggesting strain-
specific effects of IMQ on T-lymphocyte abundance
(Figs. 5b and 6d). Consistent with this, signature genes
expressed by CD4+ T-cell populations were decreased in
B6, DBA, and 129/SvJ IMQ phenotypes but unaltered or
elevated in the FVB and BALB/c phenotypes (Fig. 6b). In
agreement with this, Cd4 expression was decreased by
IMQ in B6 but not BALB/c mice (Fig. 6e; P = 2.6 × 10−3,
strain-by-treatment interaction). Genes expressed by
most CD8+ T-cell populations followed similar trends
and, indeed, the Cd8a expression pattern mirrored Cd4
(Fig. 6f; P = 0.022, strain-by-treatment interaction). How-
ever, genes expressed by effector CD8+ T cells harvested
from virus-infected mice (CD8.7e) were elevated in
nearly all IMQ phenotypes as well as human psoriasis,
with stronger increases in B6 mice compared to other
strains (Fig. 6a–c).
IMQ treatment of MOLF males induces TLR gene
expression but downregulates KC differentiation genes
localized to suprabasal epidermis
The MOLF male expression response to IMQ was nega-
tively correlated with other strains (Fig. 2c, d). Genes
specifically elevated by IMQ in MOLF males were asso-
ciated with organic acid metabolic process, brown fat
cell differentiation, type I interferon, and lipid storage
(e.g., Ifit1, Ifit3, Lep, Adipoq; Additional file 10a). Genes
specifically repressed by IMQ in MOLF males included
IL-1 family cytokines (e.g., Il1a, Il1f5, Il1f6, Il1f8, Il1f9;
Fig. 5a; Additional file 11b), as well as other genes
associated with epidermis development, peptide cross-
linking, and skin barrier establishment (e.g., Krt1,
Serpin3a, Serpin3b; Additional file 11b, f ). Consistent
with this, genes decreased by IMQ in MOLF males were
elevated in suprabasal versus basal epidermis (Fig. 7a, c)
[49], as well as during 7 days of organotypic human epi-
dermal regeneration (Fig. 7b, d) [50]. This was not the
case for other strains, however (Fig. 7a–f ). Nearly all of
the genes most strongly elevated in suprabasal epider-
mis (or during epidermal regeneration) were decreased
by IMQ in MOLF males but not other strains (e.g.,
Grhl1, Krt1, Krt78, Klk7, Dsc1; Fig. 7g, h). Using RT-
PCR, we confirmed that Il1f5 and Krt1 show different
expression responses to IMQ in B6 and MOLF mice,
with slightly decreased expression in MOLF males in
contrast to strongly elevated expression in the B6 strain
(Additional files 11c and 10d; P < 0.011, strain-by-
treatment interaction).
Previous work has shown that MOLF mice exhibit
unique responses to TLR agonists, such as lipoteichoic
acid, poly(I:C), lipopolysaccharides, cytosine guanine di-
nucleotide (CpG), and resiquimod [18, 56, 57]. A set of
101 TLR-associated genes compiled by the Kyoto
Encyclopedia of Genes and Genomes (KEGG) [58] was
disproportionately elevated by IMQ in all strains, includ-
ing MOLF males and females (Additional file 12; KEGG
pathway mmu04620). TLR1 expression was significantly
elevated by IMQ in MOLF males and females, and
MOLF males showed robust elevation of other TLR up-
stream components (TLR2, TLR6, CD14, PI3K), as well
as mRNAs encoding downstream transcription factors
(STAT1, IRF7) and cytokines (tumor necrosis factor
(TNF)-α, IL-1β, IL-6, RANTES, MIP1-α, MIP-1β)
(Additional file 12). Among all strains, expression of
TLR-associated genes was most strongly elevated in 129/
SvJ mice but most weakly elevated in CD1 mice
(Additional file 12).
Genes altered by IMQ overlap significantly with those
altered in other human skin conditions besides psoriasis
(wounding, acne, eschars, infection)
Gene expression patterns in psoriasis overlap consider-
ably with those in other human skin diseases [45]. We
therefore considered whether expression responses to
IMQ in mice were consistent with other human skin
diseases besides psoriasis (Fig. 8).
IMQ expression responses were compared to 124
expression signatures derived from microarray studies
of 35 skin diseases [45]. A match score was calculated
for each disease to quantify whether genes most
strongly increased/decreased in disease lesions were
similarly altered by IMQ (Fig. 8a). On average across all
strains, match scores for wounding (GSE8056), acne
(GSE6475), and Mediterranean spotted fever (MSF) es-
chars (GSE32993) were higher than those for psoriasis
(Fig. 8a), although significant correspondence was ob-
served for several human skin diseases (e.g., squamous
cell carcinoma, contact dermatitis, atopic eczema,
atopic dermatitis; Fig. 8a). Genes elevated by IMQ and
in MSF eschars were associated with neutrophil chemo-
taxis, defense response to bacterium, leukocyte migra-
tion, and inflammatory response (e.g., Itgam, S100a8,
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S100a9, Cxcl13; Fig. 8b, c). For six of the 14 sex–strain
combinations, the single highest match score was
obtained for psoriasis (Fig. 8d), but in other cases IMQ
responses were most similar to another disease (e.g.,
wounding and infection; Fig. 8d). Among 179 genes
elevated by IMQ in 129/SvJ females, for example, 82
were correspondingly increased in burn wound margins
(0–3 days post-injury) [51], whereas fewer (53) were el-
evated in psoriasis lesions (Fig. 8e). Likewise, among
797 genes elevated by IMQ in MOLF males, 227 were
elevated in L. braziliensis-infected cutaneous lesions
[52], but only 129 were elevated in psoriasis lesions
(Fig. 8f ).
The psoriasis-specific expression signature varies among
strains but is most closely aligned with IMQ responses in
B6 mice
All mouse strains showed expression responses to IMQ
that overlapped significantly with other human skin
diseases besides psoriasis (Fig. 8a). Compared to other
strains, however, the B6 response to IMQ was most con-
sistent with psoriasis (Additional file 8a), and for this
strain no other disease matched IMQ responses more
closely than psoriasis (Fig. 8d).
We next considered genes with a high psoriasis speci-
ficity index (PSI) identified recently from a large-scale
comparison of expression data from human skin diseases
[45]. Such genes provide a good basis for evaluation of
psoriasis mouse models since they are significantly
altered in psoriasis lesions but not similarly altered in
lesions from other skin diseases [45]. Many such genes
did not show psoriasis-like expression responses to IMQ
in any strain (e.g., Atp1b1, Dnah2, Slc8a1, Prkcb;
Additional file 13). Some psoriasis-specific genes, how-
ever, were similarly altered by IMQ, although these IMQ
responses varied among strains (Additional file 13). The
response in B6 mice best paralleled expression patterns
specific to human psoriasis (Additional file 13b, e). Only
B6 mice, for example, showed significantly decreased
expression of Fcer2, Cspg4, Lsp1, and Aldh1b1 with IMQ
treatment to recapitulate expression shifts unique to
psoriasis lesions. In contrast, IMQ responses in MOLF
males and 129/SvJ mice were least consistent with
psoriasis-specific expression shifts, and in some cases
IMQ altered expression in the direction opposite to that
observed in psoriasis lesions (Additional file 13b, e).
Discussion
The IMQ model of psoriasiform dermatitis has been
used in more than 200 mouse studies as a convenient
tool to probe mechanisms underlying psoriasis vul-
garis. The importance of strain and sex on IMQ re-
sponse has never been systematically investigated, but
may impact conclusions and interpretation of experi-
mental findings. Indeed, inattention to strain and sex
may underlie conflicting results among laboratories,
possibly even impeding translation from mouse to
humans [10, 11, 59]. Understanding these factors can
therefore bolster reproducibility of mechanistic studies
[13]. Using RNA-seq, we showed that strain and sex
influence correspondence between Aldara (5% IMQ)-
induced dermatitis and human psoriasis, suggesting
that phenotypes developing on alternative back-
grounds model the human disease to differing extents.
Strain differences were not peripherally associated
with psoriasis disease mechanisms but related to key
aspects of the pathogenesis (e.g., KC differentiation, T-
cell abundance, and IL-17A and type I interferon
responses). The transcriptional IMQ signature, more-
over, did not uniquely correspond to human psoriasis
but was consistent with diverse inflammatory skin
conditions. Consequently, the human disease best
matching IMQ expression responses varied by strain,
with psoriasis correspondence strongest in B6 mice.
Surprisingly, responses in four strains were more con-
sistent with wounding or infection (e.g., BALB/c, 129/
SvJ, DBA, MOLF).
The formation and development of psoriasis lesions
depend upon a dynamic cytokine network that involves
a multitude of interacting cell types and mediators. At
present, however, biologic therapies directed against only
a limited number of cytokines have proven clinically
effective, including TNF, IL-17A, and IL-23 [60–62]. Of
these, IL-17A may represent the most pivotal “hub”
within the cytokine network coordinating plaque devel-
opment, since TNF and IL-23 appear to positively
(See figure on previous page.)
Fig. 6 Effects of IMQ on the expression of cell type-specific genes (Immunological Genome Project). a Heatmap colors depict average IMQ
responses of 100 signature genes specifically expressed by each cell population (bottom margin; percentage of sex–strain combinations with
significantly increased (red) or decreased (blue) signature gene expression; FDR <0.05, Wilcoxon rank sum test). b Replicate CD4+ and CD8+ T
cell populations. Heatmap colors depict average IMQ responses of 100 signature genes for each T-cell population (left margin: n = naïve T cell,
m =memory T cell; e = effector T cell; magenta font indicates representative populations shown in a and c). c CD8.7e signature genes (GEO
samples GSM538387, GSM538388, and GSM605897). P values (vertical axis) quantify the degree of cell type-specific expression for each gene
(CD8.7e versus other IGP cell types, Wilcoxon rank sum test). d–f RT-PCR analysis of Cd3g (d), Cd4 (e), and Cd8 (f) expression (n= 5 per strain/sex/treatment
group; n = 40 mice total). Groups without the same letter differ significantly (P < 0.05, Tukey honest significant difference; error bars represent standard
error of the mean; p values, strain-by-treatment interaction effect). Rn18s was used as an endogenous control to estimate relative gene expression.
F female, FC fold change, M male, PN uninvolved skin from psoriasis patients, PP lesional skin from psoriasis patients, qPCR quantitative PCR
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regulate IL-17A production, in part through their influ-
ence on Th17 differentiation [3]. In this study, responses
of IL-17 family cytokines to IMQ varied, with differing
response patterns in the two most commonly studied
strains (B6 and BALB/c). In B6 mice, IMQ increased ex-
pression of Il17a, Il17b, Il17c, and Il17f, partially consist-
ent with human psoriasis, but in the BALB/c strain such
genes were unaltered by IMQ (Additional file 10). Stron-
ger elevation of IL-17 family gene expression in B6 mice
was concurrent with heightened epidermal thickness
and mitotic gene expression, along with increased ex-
pression of genes expressed by CD8+ T cells, granulo-
cytes, and ɣδ T cells (Fig. 6a). These findings conflict
with a previous study reporting that Il17a expression
was induced by IMQ in both B6 and BALB/c mice, al-
though with a faster response in BALB/c (2 days) com-
pared to B6 mice (3–4 days) [3]. Since IMQ responses
were evaluated after a longer time period in this study (6
days), however, it is unlikely that our results solely re-
flect delayed Il17a response to IMQ in B6 mice. In pre-
vious studies, manipulation of IL-17 family cytokines
appears to have only modest effects on IMQ dermatitis,
with the largest effects observed in mice lacking IL-17 F
[3, 5, 63, 64]. The main implication of our findings is
that the commonly studied B6 and BALB/c mice cannot
be regarded as interchangeable in such work and dispar-
ate responses in these strains may impact conclusions
related to this important cytokine family.
Topical IMQ was originally developed as a means to
induce anti-viral responses and type I interferon in ani-
mal models [4]. It is therefore surprising that genes asso-
ciated with viral genome replication and poly(I:C) were
among the most variably altered by IMQ, with key path-
way components activated in some strains (MOLF, 129/
SvJ, BALB/c) and repressed in others (B6, DBA, FVB)
(Fig. 4a, b). In the latter group, IMQ also led to stronger
declines in the expression of genes specifically expressed
by plasmacytoid dendritic cells (pDCs), which are con-
sidered to be the main source of IFN-α in IMQ derma-
titis [65]. Our results may reflect strain disparities in
pDC abundance, since prior studies have demonstrated
increased pDC numbers in 129/SvJ and BALB/c mice
compared to the B6 strain (blood, spleen, and lymph
nodes), along with reduced ability of B6 mice to produce
IFN-α following viral stimulation [66, 67]. The exact role
of pDCs and type I interferon in IMQ dermatitis is com-
plex with conflicting evidence. One study reported that
pDC depletion in B6 mice has little impact on IMQ
dermatitis with similar phenotypes in wild-type mice
and Ifnar1-KO mice (i.e., mice deficient for receptor 1 of
type I IFNs) [65]. A more recent study, however, indi-
cates that erythema, epidermal proliferation, and spleno-
megaly are reduced in IMQ dermatitis of Ifnar1-KO
mice (B6) [68]. Given that B6 mice exhibit relatively
weak type I interferon IMQ responses (Fig. 4a, b), the
IMQ phenotype may be attenuated more substantially
by Ifnar1 ablation on other genetic backgrounds (e.g.,
MOLF, 129/SvJ, and BALB/c).
MOLF/EiJ mice are representatives of strains com-
monly referred to as “wild-derived”, which have a unique
genetic history with divergence from classic inbred
strains occurring more than one million years ago [69].
MOLF mice thus represent a reservoir of genetic diver-
sity absent from common laboratory strains, providing a
rich genetic resource for discovering novel gene func-
tions based on previously untested allelic variants. It was
of interest to evaluate IMQ dermatitis in MOLF mice,
since previous studies have identified MOLF genetic
variants impacting Toll-like receptor (TLR) signaling,
including alleles associated with Tlr5 [57], Irak1bp1 [56],
Irak2 [70], Irak2c [71], and Cyld [72]. These variants
appear to alter immune responses of MOLF mice to
several stimuli, such as lipoteichoic acid, poly(I:C), lipo-
polysaccharide, and schistosome infection [18, 56, 70].
IMQ is a TLR7 agonist and previous work has identified
TLR7 expression in a subpopulation of mouse interfolli-
cular epidermal keratinocytes [73]. In our study, IMQ
was poorly tolerated by MOLF mice and two of ten
IMQ-treated mice died prior to completing the 5-day
treatment (see “Methods”). A previous study has demon-
strated elevated IL-6 production by MOLF macrophages
following TLR stimulation [56], which may have contrib-
uted to the mortality we observed [3]. Among MOLF
mice surviving treatment, TLR-associated genes did not
exhibit aberrant IMQ responses compared to other
strains (Additional file 12). Rather, we identified an
(See figure on previous page.)
Fig. 7 IMQ treatment of MOLF males downregulates KC differentiation genes localized to suprabasal epidermis. a Suprabasal versus basal
epidermis (GSE42114; sliding window analysis). Genes were ranked based upon their IMQ response and windows of 100 genes were tested for
enrichment in suprabasal epidermis (red, suprabasal-increased; blue, suprabasal-decreased). b Human epidermal regeneration (GSE52651; sliding
window analysis). Genes were ranked based upon their IMQ response and windows of 100 genes were tested for enrichment in regenerated epidermis
(day 7 versus day 0; red, differentiation-increased; blue, differentiation-decreased). c Suprabasal versus basal epidermis. Enrichment statistics in MOLF
and B6 males. d Human epidermal regeneration (day 7 versus day 0). Enrichment statistics in MOLF and B6 males. e, f Gene set enrichment analysis for
the top 100 IMQ-decreased genes in MOLF males (e) and B6 males (f). Cumulative overlap (vertical axis) is shown between IMQ-decreased genes and
genes ranked according to their expression in suprabasal versus basal epidermis (horizontal axis). g, h Genes most strongly elevated in suprabasal
(g) versus basal (h) epidermis and in regenerated epidermis (day 7 versus day 0 cultures). F female, FC fold change, M male, PN uninvolved skin from
psoriasis patients, PP lesional skin from psoriasis patients
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Fig. 8 Genes altered by IMQ overlap significantly with those altered in other human skin conditions besides psoriasis (eschars, acne, infection,
wounding). a Match scores. Scores represent the average fold change (FC) of the 200 genes most strongly increased in each disease (IMQ/CTL)
and the 200 genes most strongly decreased in each disease (CTL/IMQ). Diseases are ranked by average score across IMQ phenotypes. b Genes
increased in Mediterranean spotted fever (MSF) eschars and IMQ phenotypes. c GO BP terms enriched among genes increased in MSF eschars
and IMQ phenotypes. d The highest score is shown for each sex–strain combination. e 129/SvJ females. Overlap of genes increased in IMQ
dermatitis, burn wounds, and psoriasis lesions (FDR <0.10 in each case). f MOLF males. Overlap of genes increased in IMQ dermatitis, L.
braziliensis-infected cutaneous lesions, and psoriasis lesions (FDR <0.10 in each case). F female, FC fold change, M male
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aberrant epidermal response suggestive of defective KC
differentiation and barrier formation (Fig. 7). These epi-
dermal effects may be secondary to TLR-dependent and
TLR-independent acute immune responses in MOLF
mice, and consistent with this, genes associated with
IFN-α were uniquely upregulated by IMQ in MOLF
males (e.g., Ifit1, Ifit2, Ifit3; Additional file 11e). Activa-
tion of these and other immune responses in MOLF
mice may promote NALP3 inflammasome activation
and apoptosis within the epidermis [74]. Future work
will be needed to address these possibilities and identify
the locus (loci) responsible. These findings, however,
demonstrate the potential for MOLF mice, and possibly
other wild-derived strains, to exhibit cutaneous responses
differing from common laboratory strains. Further analysis
of such mice and their unique allelic diversity may be
valuable to other areas of experimental dermatology,
where established observations may be based largely upon
classic inbred strains (e.g., B6 and BALB/c).
This study is the first to report results from RNA-seq-
based comparisons of IMQ expression responses among
multiple mouse strains. Our findings are novel and
informative, but we note six study limitations. First, we
have focused on gene expression responses to IMQ. This
approach is objective and quantitative, but other aspects
of IMQ dermatitis not considered in our study, such as
histological characteristics and drug treatment re-
sponses, represent additional criteria for comparing
IMQ phenotypes among strains and to human skin dis-
eases [1]. Second, this study evaluated Aldara (5% IMQ)
at a topical dose of 62.5 mg and analyzed the resulting
phenotype after 5 days of treatment, based on our obser-
vation that the cutaneous phenotype has reached steady
state and is fully developed one day after the final appli-
cation (day 6). Given this protocol, we have not exam-
ined early inflammatory responses 24–48 hours post-
treatment, which may also differ depending upon strain
and sex [74]. Along these lines, we cannot exclude the
possibility that strain and sex differences we’ve identified
reflect kinetic differences in IMQ response, potentially
associated with strain variation in absorption [3]. Third,
to ensure comparability, we used a common treatment
protocol in all experiments, although this same protocol
may not be ideal for each strain. A lower dose or less
prolonged treatment, for example, may be appropriate
for MOLF mice. Potentially, an IMQ protocol specific-
ally tailored to each strain would achieve greater uni-
formity of IMQ responses or better transcriptional
correspondence to human psoriasis. Fourth, this study
focused exclusively on the IMQ dermatitis developing
on back skin. Ear skin is another common application
site and may yield responses different from those de-
scribed here [4]. Fifth, our analyses have focused on
IMQ responses of each strain, i.e., the expression
difference between IMQ and CTL samples. Notably, how-
ever, baseline gene expression as measured in CTL sam-
ples also varied among strains and may contribute to IMQ
response differences (Additional file 3). Sixth, control
experiments in this study were performed using a benign
lanolin-derived occlusion cream, which lacks the isostearic
acid vehicle component of the Aldara preparation. Some
effects we’ve attributed to IMQ may thus alternatively be
due to isostearic acid vehicle, although in prior work ve-
hicle effects have been limited to early responses (<24 h)
[74] rather than the day 6 phenotypes examined here.
Mechanistic studies of human psoriasis have been
hindered by the lack of an animal model that closely reca-
pitulates all aspects of the human disease [1]. To fill this
gap, many mouse phenotypes have been developed, each
with strengths and weaknesses relative to human psoriasis
[2]. IMQ dermatitis has been widely investigated as a
psoriasiform phenotype, in part due to its macroscopic ap-
pearance, histologic features, and partial dependence upon
pathways known to mediate development of the human
disease [3]. Similar to other mouse psoriasiform pheno-
types [2], this study shows that the IMQ dermatitis expres-
sion signature exhibits strong resemblance to human
psoriasis (0.05 ≤ rs ≤ 0.45; Additional file 8), with mouse–
human correlation estimates better than those reported for
other types of acute inflammatory response [75]. This cor-
respondence, however, varies among strains and was stron-
gest in B6 mice (Fig. 8d; Additional file 8a; Additional file
13b, e). It is also important to recognize that, regardless of
strain, IMQ-driven expression shifts do not uniquely match
psoriasis, but are consistent with several human skin con-
ditions (e.g., eschars, acne, infection, wounding; Fig. 8). The
basis for this correspondence is activation of core pathways
related to positive regulation of immune response, neutro-
phil chemotaxis, leukocyte migration, and bacterial defense
response (Figs. 3f and 8c). Along with this, decreased ex-
pression of homeostatic genes is a common effect of IMQ
across strains that is also observed in psoriasis and other
skin conditions (Fig. 3g; Additional file 9a). To some de-
gree, therefore, IMQ may trigger innate immune responses
and breakdown of epidermal homeostasis intrinsic to
several forms of cutaneous pathology [45].
Psoriasis is a complex genetic disease with at least 41
genetic susceptibility loci contributing to the pathogen-
esis [76], and there continues to be progress towards
deciphering the genetics of other skin diseases as well
[77]. Considering the additional influence of environ-
mental factors [78], it is tempting to argue that studies
focused exclusively on genetically homogenous inbred
mice, despite all their advantages, can never succeed in
fully replicating human diseases and their complexity [79].
An advantage of IMQ, however, is its flexibility and con-
venience as an experimental approach, which in this study
allowed us to demonstrate strain- and sex-dependent
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effects. A study of similar scale using any other proposed
model of psoriasisiform dermatitis would have been diffi-
cult or impossible. This flexibility and ease-of-use remains
the key advantage of the IMQ model and, in principle,
could allow for more robust mechanistic studies that rou-
tinely consider the roles of sex and genetic background.
Evaluation of multiple strains may lead to conflicting
results, possibly challenging observations established
from focused studies of individual strains [10, 11]. This
approach, however, should offer dividends through more
robust conclusions and stronger reproducibility of experi-
mental results [13], ultimately improving the odds that
mechanistic findings are successfully translated from mice
to inform our understanding of disease progression in hu-
man patients [10].
Conclusions
The characteristics of IMQ dermatitis have been exten-
sively investigated in prior mouse studies, with the expect-
ation that such work carries implications for human
psoriasis [3–6]. Mechanisms established by these studies,
however, may be influenced by genetic background, com-
plicating inferences with regard to human psoriasis. This
study showed that key features of the cutaneous pheno-
type generated by Aldara (5% IMQ) are influenced by
strain and sex, including features related to central aspects
of psoriasis lesion development, such as epidermal prolif-
eration, IL-17A signaling, and T lymphocyte activity. This
study also shows that gene expression patterns associated
with IMQ dermatitis, while bearing significant resem-
blance to human psoriasis, are also aligned closely with
expression signatures of other human skin diseases (e.g.,
wounding, acne, eschars, and infection). For some strains,
expression responses to IMQ were most consistent with
expression shifts observed in skin wounds or infections
(BALB/c, 129/SvJ, DBA, MOLF). Nonetheless, IMQ-
induced expression shifts on the B6 background were
more consistent with psoriasis than any other disease in-
cluded in our analyses, and overall, the B6 phenotype
matched psoriasis better than other strain phenotypes. B6
mice may therefore provide a better genetic background
than other strains for using IMQ to model psoriasis in the
laboratory mouse.
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